Medexus Pharmaceuticals (TSE:MDP) Downgraded by Stifel Canada to Hold

Stifel Canada cut shares of Medexus Pharmaceuticals (TSE:MDP) from a strong-buy rating to a hold rating in a research report sent to investors on Thursday morning,Zacks.com reports.

Other analysts have also recently issued reports about the company. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Finally, Ventum Financial upped their price target on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Medexus Pharmaceuticals has an average rating of “Buy” and a consensus price target of C$5.49.

Medexus Pharmaceuticals Stock Up 5.2 %

TSE MDP opened at C$3.21 on Thursday. The company has a market cap of C$78.74 million, a price-to-earnings ratio of 64.20 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The business’s fifty day moving average is C$3.53 and its 200 day moving average is C$2.82.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.